ZedScan by Zilico
ZedScan, Zilico’s colposcopy adjunct diagnostic, uses Electrical Impedance Spectroscopy (EIS) technology to differentiate between normal, pre-cancerous and cancerous changes in cervical cells to minimise subjectivity and improve colposcopic diagnosis accuracy. As the UK has introduced primary HPV screening, there will be a significant increase in women referred to colposcopy following a positive screening result. Colposcopy clinics will require a better way of assessing women with visually challenging abnormalities, which may not display acetowhite changes.
ZedScan helps minimise the colposcopic subjectivity by providing additional information and immediate results for a more accurate diagnosis, reassuring both the clinician and the patient.
Zilico was founded in 2006 following a successful research collaboration between the University of Sheffield and Sheffield Teaching Hospitals Foundation Trust, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN). The company now specialises in developing real-time medical diagnostics, centred on patented Electrical Impedance Spectroscopy (EIS) technology, which is applicable to a wide range of neoplastic conditions. The company prides itself on creating innovative technology that minimises subjectivity, increases diagnostic accuracy and delivers immediate results.
ZedScan™ is a unique adjunct diagnostic device that uses EIS technology to identify cell changes that cannot always be seen during standard colposcopy practice1EIS differentiates between normal, low-grade and high-grade abnormalities to minimise subjectivity and improve diagnostic accuracy1Real-world data shows 96.2% of all high-grade abnormalities were identified when ZedScan is used as an adjunct diagnostic with standard colposcopy1By providing immediate results and offering additional information, ZedScan reassures clinicians to treat at first visit, or return women to routine re-call, when no disease is present2ZedScan is easy to use and can be seamlessly integrated into standard colposcopy to support clinical decision making1
1. Macdonald, M.C., et al. (2017) “Influence of high risk HPV genotype on colposcopic performance: A large prospective study demonstrates improved detection of disease with ZedScan I, particularly on non-HPV16 patients” European Journal of Obstetrics and Gynaecology and Reproductive Biology http:/dx.doi.org/10.1016/j.ejogrb.2017.02.02.
2. Tidy, J.A., et al (2017) “Are colposcopy and electrical impedance spectroscopy complementary when used to detect high-grade cervical neoplasia?” European Journal of Gynaecological Oncology.